Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Min-Su Kang, Ilario Giovanni Rapposelli et al.|European Journal of Cancer|2024Cited by 47
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D IndexMara Persano, Lorenzo Fornaro, Margherita Rimini et al.|Liver International|2025Cited by 9
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational studyMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|International Journal of Cancer|2025Cited by 4
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide populationMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|JNCI Journal of the National Cancer Institute|2025Cited by 4
Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide PopulationMargherita Rimini, Min-Su Kang, Lorenzo Fornaro et al.|SSRN Electronic Journal|2024Cited by 3